Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
Add more filters

Complementary Medicines
Country/Region as subject
Publication year range
1.
Biomed Pharmacother ; 141: 111676, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34126353

ABSTRACT

Xijiao Dihuang decoction combined with Yinqiao powder (XDD-YQP) is a classical combination formula; however, its therapeutic effects in treating influenza viral pneumonia and the pharmacological mechanisms remain unclear. The therapeutic effect of XDD-YQP in influenza viral pneumonia was evaluated in mice. Subsequently, an everted gut sac model coupled with UPLC/Q-TOF MS were used to screen and identify the active compounds of XDD-YQP. Furthermore, network pharmacological analysis was adopted to probe the mechanisms of the active compounds. Lastly, we verified the targets predicted from network pharmacological analysis by differential bioinformatics analysis. Animal experiments showed that XDD-YQP has a therapeutic effect on influenza viral pneumonia. Moreover, 113 active compounds were identified from intestinal absorbed solutions of XDD-YQP. Using network pharmacological analysis, 90 major targets were selected as critical in the treatment of influenza viral pneumonia through 12 relevant pathways. Importantly, the MAPK signaling pathway was found to be closely associated with the other 11 pathways. Moreover, seven key targets, EGFR, FOS, MAPK1, MAP2K1, HRAS, NRAS, and RELA, which are common targets in the MAPK signaling pathway, were investigated. These seven key targets were identified as differentially expressed genes (DEGs) between influenza virus-infected and uninfected individuals. Hence, the seven key targets in the MAPK signaling pathway may play a vital role in the treatment of influenza viral pneumonia with XDD-YQP. This research may offer an integrative pharmacology strategy to clarify the pharmacological mechanisms of traditional Chinese medicines. The results provide a theoretical basis for a broader clinical application of XDD-YQP.


Subject(s)
Antiviral Agents/analysis , Drugs, Chinese Herbal/analysis , Influenza, Human/drug therapy , Network Pharmacology/methods , Pneumonia, Viral/drug therapy , Animals , Antiviral Agents/administration & dosage , Chick Embryo , Drug Therapy, Combination , Drugs, Chinese Herbal/administration & dosage , Humans , Influenza, Human/pathology , Male , Mice , Mice, Inbred BALB C , Pneumonia, Viral/pathology , Powders , Rats , Rats, Sprague-Dawley , Spectrometry, Mass, Electrospray Ionization/methods
2.
Molecules ; 25(21)2020 Oct 22.
Article in English | MEDLINE | ID: mdl-33105694

ABSTRACT

Viral infections and associated diseases are responsible for a substantial number of mortality and public health problems around the world. Each year, infectious diseases kill 3.5 million people worldwide. The current pandemic caused by COVID-19 has become the greatest health hazard to people in their lifetime. There are many antiviral drugs and vaccines available against viruses, but they have many disadvantages, too. There are numerous side effects for conventional drugs, and active mutation also creates drug resistance against various viruses. This has led scientists to search herbs as a source for the discovery of more efficient new antivirals. According to the World Health Organization (WHO), 65% of the world population is in the practice of using plants and herbs as part of treatment modality. Additionally, plants have an advantage in drug discovery based on their long-term use by humans, and a reduced toxicity and abundance of bioactive compounds can be expected as a result. In this review, we have highlighted the important viruses, their drug targets, and their replication cycle. We provide in-depth and insightful information about the most favorable plant extracts and their derived phytochemicals against viral targets. Our major conclusion is that plant extracts and their isolated pure compounds are essential sources for the current viral infections and useful for future challenges.


Subject(s)
Antiviral Agents/therapeutic use , Coronavirus Infections/drug therapy , HIV Infections/drug therapy , Hepatitis C, Chronic/drug therapy , Herpes Simplex/drug therapy , Influenza, Human/drug therapy , Phytochemicals/therapeutic use , Pneumonia, Viral/drug therapy , Antiviral Agents/chemistry , Antiviral Agents/classification , Antiviral Agents/isolation & purification , Betacoronavirus/drug effects , Betacoronavirus/pathogenicity , Betacoronavirus/physiology , COVID-19 , Coronavirus Infections/pathology , Coronavirus Infections/virology , Drug Discovery , HIV/drug effects , HIV/pathogenicity , HIV/physiology , HIV Infections/pathology , HIV Infections/virology , Hepacivirus/drug effects , Hepacivirus/pathogenicity , Hepacivirus/physiology , Hepatitis C, Chronic/pathology , Hepatitis C, Chronic/virology , Herpes Simplex/pathology , Herpes Simplex/virology , Humans , Influenza, Human/pathology , Influenza, Human/virology , Orthomyxoviridae/drug effects , Orthomyxoviridae/pathogenicity , Orthomyxoviridae/physiology , Pandemics , Phytochemicals/chemistry , Phytochemicals/classification , Phytochemicals/isolation & purification , Plants, Medicinal , Pneumonia, Viral/pathology , Pneumonia, Viral/virology , SARS-CoV-2 , Simplexvirus/drug effects , Simplexvirus/pathogenicity , Simplexvirus/physiology , Virus Internalization/drug effects , Virus Replication/drug effects
3.
Molecules ; 25(17)2020 Aug 25.
Article in English | MEDLINE | ID: mdl-32854331

ABSTRACT

Complications due to influenza are often associated with inflammation with excessive release of cytokines. The bulbs of Fritillariae thunbergii (FT) have been traditionally used to control airway inflammatory diseases, such as bronchitis and pneumonia. To elucidate active compounds, the targets, and underlying mechanisms of FT for the treatment of influenza-induced inflammation, systems biology was employed. Active compounds of FT were identified through the TCMSP database according to oral bioavailability (OB) and drug-likeness (DL) criteria. Other pharmacokinetic parameters, Caco-2 permeability (Caco-2), and drug half-life (HL) were also identified. Biological targets of FT were retrieved from DrugBank and STITCH databases, and target genes associated with influenza, lung, and spleen inflammation were collected from DisGeNET and NCBI databases. Compound-disease-target (C-D-T) networks were constructed and merged using Cytoscape. Target genes retrieved from the C-D-T network were further analyzed with GO enrichment and KEGG pathway analysis. In our network, GO and KEGG results yielded two compounds (beta-sitosterol (BS) and pelargonidin (PG)), targets (PTGS1 (COX-1) and PTGS2 (COX-2)), and pathways (nitric oxide, TNF) were involved in the inhibitory effects of FT on influenza-associated inflammation. We retrieved the binding affinity of each ligand-target, and found that PG and COX-1 showed the strongest binding affinity among four binding results using a molecular docking method. We identified the potential compounds and targets of FT against influenza and suggest that FT is an immunomodulatory therapy for influenza-associated inflammation.


Subject(s)
Anti-Inflammatory Agents , Drugs, Chinese Herbal , Fritillaria/chemistry , Influenza A virus/metabolism , Influenza, Human/drug therapy , Molecular Docking Simulation , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacokinetics , Anti-Inflammatory Agents/pharmacology , Caco-2 Cells , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/pharmacokinetics , Drugs, Chinese Herbal/pharmacology , Humans , Inflammation/drug therapy , Inflammation/metabolism , Inflammation/pathology , Influenza, Human/metabolism , Influenza, Human/pathology
4.
Mar Drugs ; 18(5)2020 May 08.
Article in English | MEDLINE | ID: mdl-32397317

ABSTRACT

Fucoidans are known to be effective inhibitors of inflammation, and of virus binding and cellular entry. Undaria pinnatifida-derived fucoidan (UPF) was assessed in a severe influenza A (H1N1, PR8) infection model in mice. Initially, UPF was gavaged at 3.52 mg daily in a treatment model. Gross lung pathology (consolidation) was significantly reduced as compared to controls. UPF was then presented as a feed supplement at a rate of either nil, 3.52 mg/day or 7.04 mg/day in a prophylactic model, dosed three days before infection. A significant improvement was observed in the clinical signs of ill-health, as well as a reduction in gross lung pathology in animals treated with the higher dose, although there was no significant reduction in lung viral titres.


Subject(s)
Dietary Supplements , Influenza, Human/diet therapy , Polysaccharides/administration & dosage , Seaweed/chemistry , Undaria/chemistry , Administration, Oral , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Humans , Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza A Virus, H1N1 Subtype/pathogenicity , Influenza, Human/diagnosis , Influenza, Human/pathology , Influenza, Human/virology , Lung/pathology , Lung/virology , Mice , Severity of Illness Index , Viral Load
5.
EBioMedicine ; 33: 218-229, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29941340

ABSTRACT

BACKGROUND: Human infections with the H7N9 virus could lead to lung damage and even multiple organ failure, which is closely associated with a high mortality rate. However, the metabolic basis of such systemic alterations remains unknown. METHODS: This study included hospitalized patients (n = 4) with laboratory-confirmed H7N9 infection, healthy controls (n = 9), and two disease control groups comprising patients with pneumonia (n = 9) and patients with pneumonia who received steroid treatment (n = 10). One H7N9-infected patient underwent lung biopsy for histopathological analysis and expression analysis of genes associated with lung homeostasis. H7N9-induced systemic alterations were investigated using metabolomic analysis of sera collected from the four patients by using ultra-performance liquid chromatography-mass spectrometry. Chest digital radiography and laboratory tests were also conducted. FINDINGS: Two of the four patients did not survive the clinical treatments with antiviral medication, steroids, and oxygen therapy. Biopsy revealed disrupted expression of genes associated with lung epithelial integrity. Histopathological analysis demonstrated severe lung inflammation after H7N9 infection. Metabolomic analysis indicated that fatty acid metabolism may be inhibited during H7N9 infection. Serum levels of palmitic acid, erucic acid, and phytal may negatively correlate with the extent of lung inflammation after H7N9 infection. The changes in fatty acid levels may not be due to steroid treatment or pneumonia. INTERPRETATION: Altered structural and secretory properties of the lung epithelium may be associated with the severity of H7N9-infection-induced lung disease. Moreover, fatty acid metabolism level may predict a fatal outcome after H7N9 virus infection.


Subject(s)
Fatty Acids/metabolism , Influenza A Virus, H7N9 Subtype/pathogenicity , Influenza, Human/virology , Lung/pathology , Aged , Chromatography, High Pressure Liquid , Female , Hospitalization , Humans , Hyperbaric Oxygenation , Influenza, Human/metabolism , Influenza, Human/pathology , Influenza, Human/therapy , Male , Metabolomics/methods , Middle Aged , Steroids/therapeutic use , Treatment Outcome
6.
BMC Complement Altern Med ; 18(1): 150, 2018 May 08.
Article in English | MEDLINE | ID: mdl-29739459

ABSTRACT

BACKGROUND: Sheng Jiang San (SJS), a multi-herb formulation, is used in treating high fever, thirsty and anxiety in ancient China and it is sometimes used to treat seasonal influenza nowadays. However, there is no evidence-based investigation and mechanism research to support the anti-influenza efficacy of SJS. This study aims at evaluating the anti-influenza effect of SJS and investigating its possible mechanism. METHODS: The inhibitory effect of SJS against different influenza virus strains on MDCK cells was examined. Influenza virus infected BALB/c mice were employed to evaluate the efficacy as in vivo model. Mice challenged with A/PR/8/34 (H1N1) were orally administrated 1 g/kg/day of SJS for seven days and monitored for 14 days. The survival rate, body weight changes, lung index, lung viral load, histopathologic changes and immune regulation of the mice were measured. The underlying anti-influenza virus mechanism of SJS was studied by a series of biological assays to determine if hemagglutinin, ribonucleoprotein complex or neuraminidase were targets of SJS. RESULTS: Results showed SJS exerted a broad-spectrum of inhibitory effects on multiple influenza strains in a dose-dependent manner. IC50 of SJS against A/WSN/33 (H1N1) was lower than 35 µg/ml. SJS also protected 50% of mice from A/PR/8/34 (H1N1) infection. The lung index and the lung viral load of SJS treated mice were significantly decreased compared with untreated mice. Meanwhile, SJS targeted on neuraminidase of influenza virus as SJS at 2 mg/ml inhibited 80% of neuraminidase enzymatic activity. SJS also significantly down-regulated TNF-α and up-regulated IL-2 of influenza virus induced mice. CONCLUSIONS: Thus, SJS is a useful formulation for treating influenza virus infection.


Subject(s)
Antiviral Agents/pharmacology , Drugs, Chinese Herbal/pharmacology , Influenza, Human/metabolism , Lung/drug effects , Neuraminidase/antagonists & inhibitors , Animals , Cytokines/analysis , Cytokines/metabolism , Disease Models, Animal , Dogs , Humans , Influenza A Virus, H1N1 Subtype/drug effects , Influenza, Human/immunology , Influenza, Human/pathology , Lung/chemistry , Lung/immunology , Lung/virology , Madin Darby Canine Kidney Cells , Mice , Neuraminidase/drug effects , Neuraminidase/metabolism
8.
J Ethnopharmacol ; 179: 146-55, 2016 Feb 17.
Article in English | MEDLINE | ID: mdl-26719287

ABSTRACT

ETHNOPHARMACROLOGICAL RELEVANCE: Mosla scabra (Thunb.) C.Y. Wu and H.W. Li has been used as a traditional medicinal herb for centuries in East Asian countries. It has antibacterial, antiviral, antioxidant, anti-inflammatory and immunomodulatory effects. In folk medicine, it is used as a remedy for the treatment of pulmonary diseases, such as fever, cold, cough, pulmonary edema and emphysema. AIM OF THE STUDY: This study was to investigate the protective mechanism of total flavonoids from M. scabra (MF) in influenza A virus (IAV)-infected mice. MATERIALS AND METHODS: The mice were infected with IAV and then were treated daily with MF for five days. At the end of the experiment, the levels of inflammatory-related cytokines (IFN-α, IL-6, TNF-α and IL-1ß) were determined by ELISA. Pathological changes of lung tissue were examined by H&E staining. The protein expressions of AQP5, p-p38, caspase-3 and NF-κB p65 were detected by western blot analysis while the gene expressions of key effectors in AQP5 and PRRs signaling pathways were detected by real-time Fluorescence Quantitative Polymerase Chain Reaction (RFQ-PCR) analysis. RESULTS: The results showed that treatment with MF at doses of 120-360mg/kg for five days to IAV-infected mice significantly attenuated IAV-induced pulmonary injury and decreased the serum levels of IL-6, TNF-α and IL-1ß, but increased IFN-α levels. MF treatment could up-regulate the mRNA expressions of TLR-7, RIG-1, TRAF6, Bcl-2, Bax, VIPR1, PKCα and AQP5 and down-regulate caspase-3 and NF-κB p65 protein expression. CONCLUSION: Treatment with MF could significantly alleviate IAV-induced pulmonary inflammation, apoptosis and water transport abnormality, which was probably through the regulation of TLR7, RIG-1 and AQP5 signaling pathway.


Subject(s)
Acute Lung Injury/drug therapy , Antiviral Agents/therapeutic use , Flavonoids/therapeutic use , Influenza A virus/drug effects , Influenza, Human/drug therapy , Lamiaceae/chemistry , Signal Transduction/drug effects , Acute Lung Injury/etiology , Animals , Antiviral Agents/pharmacology , Aquaporins/drug effects , Body Water/metabolism , Cytokines/metabolism , Flavonoids/chemistry , Flavonoids/pharmacology , Humans , Influenza, Human/metabolism , Influenza, Human/pathology , Lung/drug effects , Male , Mice , Mice, Inbred ICR , Receptors, Pattern Recognition/drug effects , Vasoactive Intestinal Peptide/metabolism
9.
Zhongguo Zhong Yao Za Zhi ; 40(19): 3845-50, 2015 Oct.
Article in Chinese | MEDLINE | ID: mdl-26975112

ABSTRACT

To study the effect of Yinghua Pinggan granule (YHPG) against influenza A/H1N1 virus in vivo and on the immunologic function of infected mice. The intranasal influenza virus infection was adopted in ICR mouse to establish the influenza virus pneumonia model. At the 3rd and 7th day after the infection, the lung index and pathologic changes in lung tissues of mice were detected. Realtime PCR and flow cytometry were employed to observe the virus load in lung tissues and the levels of CD4+, CD8+, and CD4+/CD8+ in peripheral blood. The result showed that at the 3rd and 7th day after the infection, YHPG (15, 30 g x kg(-1)) can significant decrease in the lung index and virus load in lung tissues of mice infected with influenza virus, alleviate the pathologic changes in lung tissues, significantly increase the levels of CD4+ and CD4+/CD8+ ratio and reduce the levels of CD8+ in whole blood. This indicated that YHPG can inhibit the influenza virus replication, alleviate pulmonary damage and adjust the weak immunologic function of infected mice, with a certain therapeutic effect on mice infected by H1N1 virus in vivo.


Subject(s)
Antiviral Agents/administration & dosage , Influenza A Virus, H1N1 Subtype/drug effects , Influenza, Human/drug therapy , Animals , Humans , Influenza A Virus, H1N1 Subtype/genetics , Influenza A Virus, H1N1 Subtype/physiology , Influenza, Human/pathology , Influenza, Human/virology , Lung/pathology , Lung/virology , Male , Mice , Mice, Inbred ICR , Virus Replication/drug effects
10.
PLoS One ; 9(1): e88062, 2014.
Article in English | MEDLINE | ID: mdl-24498245

ABSTRACT

Antiviral activity has been demonstrated for different tannin-rich plant extracts. Since tannins of different classes and molecular weights are often found together in plant extracts and may differ in their antiviral activity, we have compared the effect against influenza A virus (IAV) of Hamamelis virginiana L. bark extract, fractions enriched in tannins of different molecular weights and individual tannins of defined structures, including pseudotannins. We demonstrate antiviral activity of the bark extract against different IAV strains, including the recently emerged H7N9, and show for the first time that a tannin-rich extract inhibits human papillomavirus (HPV) type 16 infection. As the best performing antiviral candidate, we identified a highly potent fraction against both IAV and HPV, enriched in high molecular weight condensed tannins by ultrafiltration, a simple, reproducible and easily upscalable method. This ultrafiltration concentrate and the bark extract inhibited early and, to a minor extent, later steps in the IAV life cycle and tannin-dependently inhibited HPV attachment. We observed interesting mechanistic differences between tannin structures: High molecular weight tannin containing extracts and tannic acid (1702 g/mol) inhibited both IAV receptor binding and neuraminidase activity. In contrast, low molecular weight compounds (<500 g/mol) such as gallic acid, epigallocatechin gallate or hamamelitannin inhibited neuraminidase but not hemagglutination. Average molecular weight of the compounds seemed to positively correlate with receptor binding (but not neuraminidase) inhibition. In general, neuraminidase inhibition seemed to contribute little to the antiviral activity. Importantly, antiviral use of the ultrafiltration fraction enriched in high molecular weight condensed tannins and, to a lesser extent, the unfractionated bark extract was preferable over individual isolated compounds. These results are of interest for developing and improving plant-based antivirals.


Subject(s)
Antiviral Agents , Hamamelis/chemistry , Human papillomavirus 16/metabolism , Influenza A virus/metabolism , Influenza, Human/drug therapy , Papillomavirus Infections/drug therapy , Plant Bark/chemistry , Plant Extracts , Tannins , Animals , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Dogs , Humans , Influenza, Human/metabolism , Influenza, Human/pathology , Madin Darby Canine Kidney Cells , Papillomavirus Infections/metabolism , Papillomavirus Infections/pathology , Plant Extracts/chemistry , Plant Extracts/pharmacology , Tannins/chemistry , Tannins/pharmacology
11.
Influenza Other Respir Viruses ; 7(6): 938-44, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23170828

ABSTRACT

PURPOSE: To examine whether apparent advantages following training in meditation over exercise can be attributed to specific symptoms, functional impairments, or quality-of-life indicators assessed by the Wisconsin Upper Respiratory Symptom Survey (WURSS-24). METHODS: Results from the randomized controlled trial "Meditation or Exercise for Preventing Acute Respiratory Illness" showed mean global severity and total days of illness were worse in control (358, 8·9) compared with exercise (248, 5·1) or meditation (144, 5·0). Global severity of illness was estimated using area under the curve from daily self-reported severity scores on the WURSS-24. For this project, we estimated within-group WURSS item-level severity and between-group effect sizes (Cohen's "d" statistic) relative to control. The item-level effect sizes were grouped into (i) symptom and (ii) function and quality of life domains. RESULTS: Among the three groups, mediators showed the lowest severity estimates for 21 of 22 WURSS items. Item-level Cohen's "d" indicated most benefit was evident in WURSS items representing function and quality of life. Compared with exercise, meditation fostered larger reductions in illness severity, although due mostly to improved function and the quality of life domain (d=-0·33, P<0·001) compared with symptom domain (d=-0·22, P<0·001). CONCLUSIONS: The apparent advantage of training in meditation over exercise for reducing cold and flu illness is explained more by improved function and quality of life than by a reduction in symptom severity.


Subject(s)
Common Cold/pathology , Common Cold/psychology , Exercise , Influenza, Human/pathology , Influenza, Human/psychology , Meditation , Aged , Female , Humans , Male , Middle Aged , Quality of Life , Severity of Illness Index
12.
Pediatr Infect Dis J ; 31(4): 373-8, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22228234

ABSTRACT

BACKGROUND: Novel 2009/H1N1 influenza has significant impact on immunocompromised children with cancer; however, it is uncertain how it compares with seasonal influenza (SFlu) in this vulnerable population. We compared clinical characteristics and outcomes for these 2 infections in children with cancer and identified risk factors for progression to lower respiratory infection (LRI) and/or death. METHODS: Influenza infections confirmed by positive viral culture and/or fluorescence antigen test between January 1998 and February 2010 were identified from microbiology databases at a comprehensive cancer center. Characteristics and outcomes were compared for the 2 groups. Kaplan-Meier survival curves and Cox proportional hazards model were generated to identify risk factors for LRI and/or death. RESULTS: When compared with SFlu, 2009/H1N1 cases had significantly lower acute physiology and chronic health evaluation II score (median: 9 versus 14), fewer comorbidities (15% versus 46%), fewer hematopoietic stem-cell transplantation (5% versus 16%), more solid tumors (45% versus 16%), higher LRI at presentation (20% versus 4%), higher rates of antiviral therapy (90% versus 48%) and higher mortality (10% versus 0%). Male gender (hazard ratio [HR]: 8.4, 95% confidence interval [CI]: 1.08-65.2, P = 0.042), acute physiology and chronic health evaluation II score > 15 (HR: 3.29, 95% CI: 1.04-10.39, P = 0.027) and a 24-hour delay in initiation of antiviral treatment (HR: 1.12, 95% CI: 1.02-1.23, P = 0.015) were the most significant predictors of progression to LRI and mortality, regardless of virus strain. CONCLUSIONS: Significant differences between 2009/H1N1 and SFlu with respect to clinical presentation, management and associated outcomes were identified. Early diagnosis and prompt initiation of antiviral therapy may prevent serious complications of influenza in children with cancer.


Subject(s)
Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza, Human/mortality , Influenza, Human/pathology , Neoplasms/complications , Pandemics , Pneumonia, Viral/epidemiology , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Influenza A Virus, H1N1 Subtype/pathogenicity , Influenza, Human/epidemiology , Influenza, Human/virology , Male , Retrospective Studies , Survival Analysis , Treatment Outcome
13.
Immunopharmacol Immunotoxicol ; 33(3): 433-7, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21039315

ABSTRACT

This study investigated the effect of the extract of Bupleuri Radix (BRE) on the infection of Madin-Darby Canine Kidney (MDCK) cells by anti-H1N1 virus. The effect of BRE on RANTES (the chemokine regulated on activation, normal T cells expressed and secreted) secretion in H1N1-infected A549 cells (human bronchial epithelial cells) was evaluated via quantative measurement of the changes in the cytopathic effects and by the ultraviolet (UV) absorbance at 600 nm. It was found that BRE was toxic to MDCK cells at a higher concentration while had a marked inhibitory effect on cell pathological changes at a lower concentration. Results also showed that BRE possessed more than 50% suppressing effect on RANTES secretion in H1N1-infected A549 cells at a concentration of 100 and 200 µg/ml. Our findings show that BRE has a significant protective effect on MDCK cells infected in a dose-dependent manner with an excellent suppressing effect on RANTES secretion, suggesting that BRE can be developed as an antivirus agent.


Subject(s)
Antiviral Agents/pharmacology , Influenza A Virus, H1N1 Subtype/physiology , Influenza, Human/drug therapy , Plant Extracts/pharmacology , Animals , Bronchi/drug effects , Bronchi/metabolism , Bronchi/pathology , Bronchi/virology , Bupleurum , Cell Line , Cell Line, Tumor , Chemokine CCL5/antagonists & inhibitors , Cytopathogenic Effect, Viral/drug effects , Dogs , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Epithelial Cells/pathology , Epithelial Cells/virology , Fruit/chemistry , Humans , Influenza, Human/metabolism , Influenza, Human/pathology , Influenza, Human/virology
14.
Pediatr Infect Dis J ; 30(4): 284-8, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21048522

ABSTRACT

BACKGROUND: Immunocompromised patients are highly susceptible to influenza infection and can have prolonged viral shedding, which is a risk factor for the development of antiviral resistance. METHODS: We investigated the emergence of oseltamivir-resistant influenza variants in children and young adults with cancer during the 2002-2008 influenza seasons. The demographic and clinical features of influenza infections in 12 patients who had viral isolates obtained before and after oseltamivir therapy was initiated were studied. Antiviral susceptibilities were determined by the fluorescence-based neuraminidase (NA) enzyme inhibition assay and by sequencing genes encoding NA and matrix M2 proteins. RESULTS: The mean age of patients was 10.5 (range, 1.1-23.0) years. Ten patients had hematologic malignancies, 4 were recipients of hematopoietic stem cell transplants, and all patients were receiving immunosuppressive therapy. Eleven patients had prolonged respiratory symptoms and 8 had prolonged viral shedding. Serial viral isolates were available for 8 of 12 patients. Oseltamivir-resistant influenza viruses were isolated from 4 children (3 influenza A [H3N2] and 1 influenza B virus): before the initiation of antiviral therapy in 2 patients and during therapy in the other 2 patients. Three resistant influenza A (H3N2) viruses shared a common E119V NA mutation. One patient was infected with oseltamivir-resistant influenza B virus (IC50, 731.86 ± 155.12 nM) that harbored a N294S NA mutation, the first report of this mutation in influenza B viruses. CONCLUSIONS: Oseltamivir-resistant influenza viruses can exist before or rapidly emerge during antiviral therapy in immunocompromised individuals, and this has important implications for therapy and infection control.


Subject(s)
Antiviral Agents/pharmacology , Drug Resistance, Viral , Influenza A virus/drug effects , Influenza B virus/drug effects , Influenza, Human/drug therapy , Neoplasms/complications , Oseltamivir/pharmacology , Adolescent , Child , Child, Preschool , Humans , Immunocompromised Host , Infant , Influenza A virus/isolation & purification , Influenza B virus/isolation & purification , Influenza, Human/pathology , Influenza, Human/virology , Microbial Sensitivity Tests , Neuraminidase/genetics , Sequence Analysis, DNA , Viral Matrix Proteins/genetics , Viral Proteins/genetics , Young Adult
15.
Brain Pathol ; 20(1): 261-4, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20438486

ABSTRACT

A 7 year old Chinese boy died of a rapidly progressive encephalopathy after influenza infection. MRI showed bilateral and symmetrical lesions including the thalamus and brainstem tegmentum. The pathology of necrosis and vasculopathy were in keeping with acute necrotizing encephalopathy (ANE). ANE was first described in Japan and carries a high mortality and morbidity. A vasculopathy with breakdown of the blood-brain-barrier was incriminated but the pathogenesis remained obscure and autopsy studies have been limited. A review of the literature showed only nine postmortem reports in the acute stage. Symmetrical brain necrosis always involved the thalamus followed by the tegmentum of the pons and other regions. Exudative vasculopathy was commonly observed and often accompanied by endothelial cell necrosis. In the present case there was inflammatory fibrinoid vasculitis which has not been previously described.


Subject(s)
Influenza, Human/pathology , Leukoencephalitis, Acute Hemorrhagic/pathology , Asthma/complications , Brain Stem/pathology , Cerebellum/pathology , Child , Fatal Outcome , Glasgow Coma Scale , Humans , Influenza A Virus, H1N1 Subtype , Influenza, Human/complications , Leukoencephalitis, Acute Hemorrhagic/etiology , Magnetic Resonance Imaging , Male , Thalamus/pathology
16.
J Am Coll Nutr ; 26(5): 445-52, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17914132

ABSTRACT

OBJECTIVE: Determine if a specific formulation of Camellia sinensis (CSF) can prevent illness and symptoms due to cold and flu, and enhance gammadelta T cell function DESIGN: Randomized, double-blind, placebo-controlled study. SUBJECTS: Healthy adults 18-70 years old. INTERVENTION: Proprietary formulation of Camellia sinensis (green tea) capsules, or a placebo, twice a day, for 3 months. MEASURES OF OUTCOME: As assessed by daily symptom logs, percentage of subjects experiencing cold and flu symptoms, number of days subjects experienced symptoms, and percentage of subjects seeking medical treatment. Mean in vivo and ex vivo proliferative and interferon gamma responses of subjects' peripheral blood mononuclear cells to gammadelta T cell antigen stimulation. RESULTS: Among subjects taking CSF there were 32.1% fewer subjects with symptoms (P = 0.035), 22.9% fewer overall illnesses of at least 2 days duration (P = 0.092), and 35.6% fewer symptom days (P < 0.002), compared to subjects taking placebo. gammadelta T cells from subjects taking CSF proliferated 28% more (P = 0.017) and secreted 26% more IFN-gamma (P = 0.046) in response to gammadelta T cell antigens, as compared to gammadelta T cells from subjects taking placebo. CSF was well-tolerated. CONCLUSIONS: This proprietary formulation of CSF is a safe and effective dietary supplement for preventing cold and flu symptoms, and for enhancing gammadelta T cell function.


Subject(s)
Camellia sinensis/chemistry , Common Cold/pathology , Immunity, Cellular/drug effects , Influenza, Human/pathology , Phytotherapy , T-Lymphocytes/immunology , Adult , Aged , Common Cold/immunology , Common Cold/prevention & control , Dietary Supplements , Double-Blind Method , Female , Flow Cytometry , Humans , Immunity, Cellular/physiology , Influenza, Human/immunology , Influenza, Human/prevention & control , Interferon-gamma/metabolism , Lymphocyte Activation/drug effects , Male , Middle Aged , Severity of Illness Index , Time Factors , Treatment Outcome
17.
Clin Appl Thromb Hemost ; 13(2): 130-6, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17456621

ABSTRACT

The efficacy of a 2-month treatment with oral colostrum in the prevention of flu episodes compared with antiinfluenza vaccination was evaluated. Groups included healthy subjects without prophylaxis and those receiving both vaccination and colostrum. After 3 months of follow-up, the number of days with flu was 3 times higher in the non-colostrum subjects. The colostrum group had 13 episodes versus 14 in the colostrum + vaccination group, 41 in the group without prophylaxis, and 57 in nontreated subjects. Part 2 of the study had a similar protocol with 65 very high-risk cardiovascular subjects, all of whom had prophylaxis. The incidence of complications and hospital admission was higher in the group that received only a vaccination compared with the colostrum groups. Colostrum, both in healthy subjects and high-risk cardiovascular patients, is at least 3 times more effective than vaccination to prevent flu and is very cost-effective.


Subject(s)
Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/immunology , Colostrum/immunology , Health , Influenza Vaccines/immunology , Influenza, Human/immunology , Influenza, Human/prevention & control , Adult , Aged , Aged, 80 and over , Cardiovascular Diseases/pathology , Female , Humans , Immune Tolerance/immunology , Influenza Vaccines/economics , Influenza, Human/epidemiology , Influenza, Human/pathology , Italy/epidemiology , Male , Middle Aged , Risk Factors
20.
AJNR Am J Neuroradiol ; 16(3): 439-47, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7793361

ABSTRACT

PURPOSE: To investigate the imaging and pathologic characteristics of acute encephalopathy with bilateral thalamotegmental involvement in infants and children. METHODS: Five Japanese children ranging in age from 11 to 29 months were studied. We performed CT imaging in all patients, 10 MR examinations in four patients, and an autopsy in one patient. RESULTS: The encephalopathy affected the thalami, brain stem tegmenta, and cerebral and cerebellar white matter. The brain of the autopsied case showed fresh necrosis and brain edema without inflammatory cell infiltration. Petechiae and congestion were demonstrated mainly in the thalamus. CT and MR images showed symmetric focal lesions in the same areas in the early phase. These lesions became more demarcated and smaller in the intermediate phase. The ventricles and cortical sulci enlarged. MR images demonstrated T1 shortening in the thalami. The prognosis was generally poor; one patient died, three patients were left with severe sequelae, and only one patient improved. CONCLUSIONS: The encephalopathy might be a postviral or postinfectious brain disorder. T1 shortening in the thalami indicated the presence of petechiae.


Subject(s)
Brain Damage, Chronic/diagnosis , Dominance, Cerebral/physiology , Encephalitis/diagnosis , Magnetic Resonance Imaging , Tegmentum Mesencephali/pathology , Thalamus/pathology , Tomography, X-Ray Computed , Acute Disease , Antibodies, Viral/blood , Brain Damage, Chronic/pathology , Brain Stem/pathology , Cerebral Cortex/pathology , Child, Preschool , Diagnosis, Differential , Encephalitis/pathology , Encephalitis, Viral/diagnosis , Encephalitis, Viral/pathology , Female , Humans , Infant , Influenza, Human/diagnosis , Influenza, Human/pathology , Japan , Male , Measles/diagnosis , Measles/pathology
SELECTION OF CITATIONS
SEARCH DETAIL